Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insights Into a "Negative" ICU Trial Derived From Gene Expression Profiling.

Mary Hoekstra1, David M Maslove, Richard A Veldhoen2

  • 1Department of Critical Care Medicine, Queen's University, Kingston, ON, Canada.

Critical Care Medicine
|March 1, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mass cytometry reveals complex neutrophil heterogeneity in patients with severe sepsis.

Intensive care medicine experimental·2026
Same author

Ceragenin-Coated Endotracheal Tubes for the Reduction of Ventilator-Associated Pneumonia: A Prospective, Longitudinal, Crossover, Interrupted Time, Implementation Study (CEASE VAP Study).

Critical care explorations·2026
Same author

Feasibility of Calculating and Maintaining Near-Infrared Spectroscopy-Guided Personalized Mean Arterial Pressure Targets in Adults With Critical Illness: A Pilot Clinical Study.

Critical care explorations·2026
Same author

Prophylaxis for venous thromboembolism in traumatic brain injury: protocol for a randomised controlled trial.

BMJ open·2025
Same author

The authors reply.

Critical care medicine·2025
Same author

Effect of Monetary Incentives on Peer Review Acceptance and Completion: A Quasi-Randomized Interventional Trial: Erratum.

Critical care medicine·2025

Transcriptomic analysis of a negative clinical trial revealed no randomization imbalance. The study drug, lactoferrin, did show gene expression changes in immune pathways, suggesting clinical outcomes may lack sensitivity.

Area of Science:

  • Critical care medicine
  • Molecular biology
  • Bioinformatics

Background:

  • Randomized controlled trials (RCTs) in intensive care units (ICUs) often yield negative results, with no significant differences in endpoints between treatment groups.
  • Understanding molecular-level reasons for trial outcomes is crucial for improving future study design and interpretation.

Purpose of the Study:

  • To analyze transcriptomic data from a negative ICU trial to identify reasons for the lack of observed clinical differences.
  • To assess the effectiveness of randomization in balancing transcriptomic profiles between study groups.
  • To evaluate transcriptomic heterogeneity among critically ill patients and determine the effect of the study drug (lactoferrin) on gene expression.

Main Methods:

  • Bioinformatics analysis of transcriptomic and clinical data from a randomized controlled trial.

Related Experiment Videos

  • Inclusion of adult, critically ill patients requiring prolonged mechanical ventilation.
  • Intervention involved enteral and oral lactoferrin or placebo for up to 28 days.

    • Main Results:

    • No significant imbalances in transcriptomic features were found between the lactoferrin and placebo groups.
    • Unsupervised analysis did not identify distinct patient clusters at enrollment, indicating broad patient similarity at the transcriptomic level.
    • Significant differences in gene expression were observed over time, and lactoferrin treatment altered the expression of immune-related genes.

    Conclusions:

    • Transcriptomic data complements clinical findings, suggesting the negative trial outcome was more likely due to the low sensitivity of clinical endpoints rather than the lack of biological efficacy of lactoferrin.
    • Transcriptomics may serve as a valuable tool in future studies for predicting patient response to treatments.
    • Further investigation into molecular markers could enhance the power and interpretability of critical care clinical trials.